Intra-amniotic administration of EDI200 for the treatment of ectodermal dysplasias
US10300013B2 · kind B2 · utility
0Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 21, 2014 |
| Grant date | May 28, 2019 |
| Priority date | — |
| Expiry date | Nov 12, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods for the intra-amniotic administration of EDA agonists, in particular EDI200. Use of the methods described allow for the design of targeted therapeutic dosing and administration regimens in order to correct or alter abnormal phenotypes associated with ectodermal dysplasias, in particular, XLHED.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.